December 11, 2014 /3BL Media/ – Today, Novo Nordisk published a new issue of its quarterly sustainability magazine, TBL Quarterly. Last year, Novo Nordisk invested DKK 10.9 billion (approx. EUR 1.46 billion) in research and development (R&D) thereby supporting new drug development, global research collaboration and job creation.
In the new TBL Quarterly, Under the microscope: There’s more to R&D than meets the eye , Novo Nordisk employees discuss how science is making a positive contribution to health, society and the environment.
